Get the Stockscreener App
6.65
6.91%
0.43
Ardelyx Inc stock is traded at $6.65, with a volume of 3.94M.
It is up +6.91% in the last 24 hours and down -9.89% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$6.22
Open:
$6.3
24h Volume:
3.94M
Relative Volume:
0.90
Market Cap:
$1.63B
Revenue:
$386.15M
Net Income/Loss:
$-56.39M
P/E Ratio:
-28.91
EPS:
-0.23
Net Cash Flow:
$-55.19M
1W Performance:
+1.37%
1M Performance:
-9.89%
6M Performance:
+1.22%
1Y Performance:
+22.92%
1-Day Range:
$6.13
$6.69
1-Week Range:
$6.08
$6.69
52-Week Range:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
6.65 | 1.53B | 386.15M | -56.39M | -55.19M | -0.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
Biotech firm Ardelyx heads to Miami for back-to-back investor events - Stock Titan
ARDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ardelyx (NASDAQ:ARDX) Stock Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Ardelyx LPGA Partnership Puts Spotlight On Women’s Digestive Health And Growth - simplywall.st
Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance - simplywall.st
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership - The Globe and Mail
Revisiting ArdelyxInsider Weekends (NASDAQ:ARDX) - Seeking Alpha
ARDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ardelyx, Inc. (ARDX) Investor Outlook: Analysts See A Potential 142% Upside - DirectorsTalk Interviews
Ardelyx goes full swing with the LPGA for IBS-C awareness - Medical Marketing and Media
ARDELYX (NASDAQ: ARDX) CEO Raab sells 41,666 shares after option exercise - Stock Titan
Ardelyx (ARDX) Price Target Increased by 10.08% to 16.20 - Nasdaq
Ardelyx (ARDX) Partners with LPGA to Promote IBS-C Awareness - GuruFocus
Proposed ARDX share sales and insider sale (ARDX) by Michael G. Raab - Stock Titan
Ardelyx Becomes Marketing Partner of Ladies Professional Golf Association - marketscreener.com
Hedge Fund and Insider Trading News: Paul Singer, David Tepper, Warren Buffett, Bill Ackman, Caxton Associates, Bridgewater Associates, Hycroft Mining Holding Corporation (HYMC), Ardelyx Inc (ARDX), and More - Insider Monkey
Insider Stock Purchases: February 24, 2026 - Quiver Quantitative
Ardelyx, Inc. Stock Hits Day Low of $5.55 Amid Price Pressure - Markets Mojo
Ardelyx (NASDAQ:ARDX) Shares Gap Up Following Insider Buying Activity - MarketBeat
Ardelyx gains after insider purchase (update) (ARDX:NASDAQ) - Seeking Alpha
Is Ardelyx Inc. stock a buy or sell2025 Volatility Report & AI Enhanced Trading Alerts - mfd.ru
Ardelyx (ARDX) Partners with LPGA to Champion Women's Health - GuruFocus
Ardelyx and the LPGA announce multi-year partnership - marketscreener.com
Ardelyx and the LPGA Announce Multi-Year Partnership to - GlobeNewswire
Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update - simplywall.st
Ardelyx Insider Bought Shares Worth $1,946,331, According to a Recent SEC Filing - marketscreener.com
Millions of women suffer IBS-C in silence; LPGA and Ardelyx team up - Stock Titan
ARDX stock jumps over 5% overnight as director loads up in vote of confidence for flagship constipation drug - MSN
Ardelyx (ARDX) Valuation Check After 2025 Results And Strong 2026 Growth Guidance - Yahoo Finance
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Insider Buying: David Mott Acquires 333,333 Shares of Ardelyx In - GuruFocus
Piper Sandler reiterates Ardelyx stock rating on Ibsrela growth By Investing.com - Investing.com UK
Ardelyx SVP Reilly sells $29k in shares to cover tax obligations - Investing.com UK
Ardelrx director David Mott buys $1.94m in shares By Investing.com - Investing.com South Africa
Insider Selling: Ardelyx (NASDAQ:ARDX) Insider Sells $47,829.60 in Stock - MarketBeat
Ardelyx (NASDAQ:ARDX) Insider John Bishop Sells 3,179 Shares - MarketBeat
Ardelyx (NASDAQ:ARDX) Insider James Parker Brady Sells 2,543 Shares - MarketBeat
Ardelyx (NASDAQ:ARDX) Director Purchases $1,946,664.72 in Stock - MarketBeat
Ardelyx (NASDAQ: ARDX) CCO sells 10,439 shares in RSU tax sale - Stock Titan
Williams Laura a, chief patient officer, sells ARDX stock for $47803 - Investing.com UK
Williams Laura a, chief patient officer, sells ARDX stock for $47803 By Investing.com - Investing.com South Africa
Hohenleitner Susan, Ardelyx CFO, sells $11.9k in ARDX stock By Investing.com - Investing.com South Africa
Hohenleitner Susan, Ardelyx CFO, sells $11.9k in ARDX stock - Investing.com Nigeria
Ardelux: chief human resources officer Brady sells $14,867 in stock - Investing.com
ARDX (NASDAQ: ARDX) amended Form 144 shows planned sale tied to RSU vesting - Stock Titan
Ardelyx: collective momentum drives company achievements - Traders Union
Piper Sandler reiterates Ardelyx stock rating on Ibsrela growth - Investing.com India
Analyst Wedbush Reiterates Outperform Rating for Ardelyx (ARDX) with $19 Price Target | ARDX Stock News - GuruFocus
Ardelyx Inc: Leerink Partners raises target price to $17 from $11 - marketscreener.com
Assessing Ardelyx (ARDX) Valuation After Strong IBSRELA Growth And Upbeat 2026 Revenue Guidance - simplywall.st
Ardelyx Earnings Call: IBSRELA Fuels Growth Story - TipRanks
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):